510(k) Includes New Clinical Data to Support EDAP's File LYON, France , September 11, 2017 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that the Company submitted a new 510(k) application for its Focal One device, including an updated clinical section

    University of Chicago Medicine - Dr. A. Shalhav, Chair of Urology Surgery and Director of Robotic Surgery  Vituro Health LLC - Dr. S. Scionti , Medical Director and Director of The Scionti Prostate Center in Sarasota, FL LYON, France , September 19, 2017 -- EDAP TMS SA (Nasdaq:EDAP), the global

LYON, France , October 4, 2017 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced FDA approval of its Ablatherm-Fusion device enabling a more precise method for targeting of diagnosed areas within the prostate. Marc Oczachowski , Chief Executive Officer of

EDAP to Market Echotherapy for ablation of breast fibroadenomas and benign thyroid nodules LYON, France , October 9, 2017 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the signature of an Agreement with French HIFU Company Theraclion, to exclusively

Contact: Blandine Confort Investor Relations / Legal Affairs EDAP TMS SA +33 4 72 15 31 72 bconfort@edap-tms.com Investors: Rich Cockrell CG CAPITAL 877.889.1972 rich@cg.capital   Conference Call to Review Results to be Held Thursday, November 16, 2017 LYON, France , November 01, 2017 - EDAP TMS SA

EDAP TMS Reports Third Quarter 2017 Results  EDAP's HIFU patient treatment revenues grew 29% compared to third quarter 2016. EDAP received FDA clearance for its Ablatherm Fusion ®  late in the quarter. EDAP's cash position remains strong at US $21.3 million on September 30, 2017 LYON, France ,

  LYON, France , December 18, 2017 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced the first HIFU treatments performed at Acibadem Hospital , Istanbul, Turkey , using the Company's Focal One Robotic HIFU device.   Prof.

LYON, France , March 14, 2018 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the year ended December 31, 2017 , after the close of the financial markets on Tuesday, March 27, 2018 .

Insurer Takes its Cue from Updated NCCN Guidelines, Which Recognizes HIFU as Salvage Treatment for Prostate Cancer Lyon, France , Austin, TX -- March 21, 2018 - EDAP TMS SA (Nasdaq: EDAP) today announced that CIGNA became the first major U.S. private health insurance company to reimburse prostate

2017 Highlights 2017 revenue on par with 2016; lower HIFU capital equipment sales offset by double-digit HIFU treatment revenue growth   CMS issued C-Code allocation for reimbursement of HIFU for prostate tissue ablation in July CIGNA to reimburse HIFU as salvage therapy for prostate cancer